Clinical trials
catalyst calendar across sponsors →Studies where ADPT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 observational
Held by 15 tracked-famous managers (VIKING GLOBAL INVESTORS LP, D. E. Shaw & Co., Inc., JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, Qube Research & Technologies Ltd, +10 more) · FINRA short interest 4.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 9 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR TherapyNCT05255354observationalPrimary Outcome: Predicting Progression Free Survival | — | Recruiting | Device: ClonoSEQ | Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma | 300 | 2025-09-01 | 2024-08-22 |
| The clonoSEQ® Watch RegistryNCT04545333observationalDistribution of timepoints at which MRD is monitored using the clonoSEQ Assay in lymphoid malignancy patients in real world settings | — | Terminatedsponsor's stated reason: Sufficient data collected. | Diagnostic test: clonoSEQ Assay | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia, Multiple Myeloma, Non-hodgkin Lymphoma | 465 | 2023-10-01actual | 2024-08-01 |
| ImmuneSense™ IBD StudyNCT05769829observationalSensitivity and specificity of T-Detect IBD | — | Terminatedsponsor's stated reason: Enrollment challenges for cohort 2 | — | Inflammatory Bowel Diseases | 484 | 2023-08-14actual | 2023-10-05 |
| ImmuneSense™ COVID-19 Cross-Reactivity StudyNCT05112874observationalCross-Reactivity of T-Detect COVID | — | Withdrawnsponsor's stated reason: Flu season over. | — | Coronavirus Disease, SARS-CoV-2 Infection | 0 | 2023-05-17actual | 2023-07-27 |
| ImmuneSense COVID-19 Variant StudyNCT05054088observationalPrimary Objective: Positive Percent Agreement | — | Completed | Device: T-Detect COVID test | Covid19 | 203 | 2022-07-20actual | 2022-12-07 |
| ImmuneSense Lyme StudyNCT04422314observationalTo evaluate sensitivity of T-Detect Lyme Assay relative to STTT and MTTT | — | Completed | Diagnostic test: T-Detect Lyme | Lyme Disease | 893 | 2021-10-29actual | 2022-04-15 |
| ImmuneRACE - Immune Response Action to COVID-19 EventsNCT04494893observationalComparison of disease-specific TCR signatures in patients and controlsStudy Protocol ↗ · Informed Consent Form ↗ | — | Completed | — | Covid19 | 808 | 2021-03-23actual | 2022-02-16 |
| ImmuneSense™ COVID-19 StudyNCT04583982observationalDemonstrate clinical agreement of T-Detect™ SARS-CoV-2 Assay | — | Completed | Other: T-Detect™ SARS-CoV-2 Assay | Coronavirus Disease (COVID-19), SARS-CoV-2 Infection | 180 | 2020-12-04actual | 2022-04-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19